Anavex Life Sciences Corp. (NASDAQ:AVXL) and Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) compete with each other in the Biotechnology sector. We will analyze and compare their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anavex Life Sciences Corp.	N/A	0.00	20.73M	-0.46	0.00
Verrica Pharmaceuticals Inc.	N/A	0.00	20.65M	-0.63	0.00

Demonstrates Anavex Life Sciences Corp. and Verrica Pharmaceuticals Inc. earnings per share, top-line revenue and valuation.

Profitability

Table 2 has Anavex Life Sciences Corp. and Verrica Pharmaceuticals Inc.’s return on equity, return on assets and net margins.

	Net Margins	Return on Equity	Return on Assets
Anavex Life Sciences Corp.	0.00%	-99%	-83.6%
Verrica Pharmaceuticals Inc.	0.00%	0%	0%

Liquidity

The Current Ratio and a Quick Ratio of Anavex Life Sciences Corp. are 4.5 and 4.5. Competitively, Verrica Pharmaceuticals Inc. has 40.3 and 40.3 for Current and Quick Ratio. Verrica Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than Anavex Life Sciences Corp.

Analyst Ratings

Anavex Life Sciences Corp. and Verrica Pharmaceuticals Inc. Recommendations and Ratings are available on the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Anavex Life Sciences Corp.	0	0	0	0.00
Verrica Pharmaceuticals Inc.	0	0	1	3.00

Competitively the average target price of Verrica Pharmaceuticals Inc. is $20, which is potential 89.21% upside.

Insider and Institutional Ownership

Institutional investors held 14.1% of Anavex Life Sciences Corp. shares and 33% of Verrica Pharmaceuticals Inc. shares. Anavex Life Sciences Corp.’s share held by insiders are 5.32%. Comparatively, Verrica Pharmaceuticals Inc. has 44.5% of it’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Anavex Life Sciences Corp.	7.02%	40%	10.21%	-1.15%	7.92%	66.03%
Verrica Pharmaceuticals Inc.	14.99%	5.76%	8.39%	-26.22%	0%	55.34%

For the past year Anavex Life Sciences Corp.’s stock price has bigger growth than Verrica Pharmaceuticals Inc.

Summary

Verrica Pharmaceuticals Inc. beats Anavex Life Sciences Corp. on 5 of the 7 factors.

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of AlzheimerÂ’s disease, other central nervous system diseases, pain, and various cancers. The companyÂ’s lead drug candidates include ANAVEX 2-73, a Phase 2a clinical trial for the treatment of AlzheimerÂ’s disease; and preclinical stage to treat ParkinsonÂ’s disease. Its preclinical drug candidates include ANAVEX 3-71, which uses ligands that activate sigma-1 and M1 muscarinic receptors to treat AlzheimerÂ’s disease; ANAVEX 1-41, a sigma-1 agonist that protects nerve cells from degeneration or death; ANAVEX 1037 for the treatment of prostate cancer; and ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the treatment of neuropathic and visceral pain. The company was founded in 2006 and is based in New York, New York.

Verrica Pharmaceuticals Inc. develops and commercializes dermatological treatments in the United States. The company is advancing its lead product VP-102, a proprietary topical therapy, in various common skin indications, including Molluscum contagiosum and Verruca Vulgaris. It is also developing 2 Phase 3 trials in molluscum contagiosum under NCT03377803 and NCT03377790. The company is headquartered in West Chester, Pennsylvania.